Our Mission
Our Story
Search
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Update on LUME-Meso Clinical Trial
Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.
CIA Reporting Requirements
CIA Reporting Requirements
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge
Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Volunteering to Strengthen the Human-Animal Bond
Volunteering to Strengthen the Human-Animal Bond
Sunshine Act Compliance
Sunshine Act Compliance
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Consumer Health Data Privacy Statement
This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.